Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)

Journal of Cellular Physiology

Volumn 222, Issue 2, 2010, Pages 357-364

  Zauli, Giorgio ^a   Rimondi, Erika ^a   Celeghini, Claudio ^b   Milani, Daniela ^a   Secchiero, Paola ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; DEATH RECEPTOR 5; DEXAMETHASONE; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; MOLECULAR MECHANICS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL LINEAGE; CELL PROLIFERATION; CELL STRAIN HL 60; DOSE RESPONSE; DRUG EFFECT; LEUKEMIA; METABOLISM; MONONUCLEAR CELL; OSTEOBLAST; PATHOLOGY; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GLUCOCORTICOIDS; HL-60 CELLS; HUMANS; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOBLASTS; RANK LIGAND; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 73349128771     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21960     Document Type: Article

References (37)

1. Ashkenazi A. 2008. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325-331.
2. Borgatti P, Zauli G, Colamussi ML, Gibellini D, Previati M, Cantley LL, Capitani S. 1997. Extracellular HIV-1 Tat protein activates phosphatidylinositol 3- and Akt/PKB kinases in CD4+ T lymphoblastoid Jurkat cells. Eur J Immunol 27:2805-28011.
3. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G. 2005. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166: 557-563.
4. Chamoux E, Houde N, L'Eriger K, Roux S. 2008. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 216:536-542.
5. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. 2007. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 12:1623-1632.
6. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. 2003. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63:3112-3120.
7. Heymann D, Ory B, Gouin F, Green JR, Rédini F. 2004. Bisphosphonates: New therapeutic agents for the treatment of bone tumors. Trends Mol Med 10:337-343.
8. Hirayama T, Sabokbar A, Athanasou NA. 2002. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol 175:155-163.
9. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. 2006. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592-5599.
10. Kim YH, Jun JH, Woo KM, Ryoo HM, Kim GS, Baek JH. 2006a. Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of b3 integrin expression. Arch Pharm Res 29:691-698.
11. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. 2006b. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160.
12. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL. 2007. Glucocorticoids and the osteoclast. Ann NY Acad Sci 1116:335-339.
13. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC, Evdokiou A. 2009. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15:1998-2009.
14. Lam V, Findley HW, Reed JC, Freedman MH, Goldenberg GJ. 2002. Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines. Leuk Res 26:503-513.
15. Lo Cascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, Della Rocca C. 1990. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39-51.
16. Matsuhashi Y, Tasaka T, Uehara E, Fujimoto M, Fujita M, Tamura T, Honda T, Kuwajima M, Shimoura Y,Mano S, Nagai M, Ishida T. 2004. Diffuse large B-cell lymphoma presentingwith hypercalcemia and multiple osteolysis. Leuk Lymphoma 45:397-400.
17. Meng RD, El-Deiry WS. 2001. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 262:154-169.
18. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. 2006. Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5:933-940.
19. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. 1998. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801-806.
20. Petrella A, Ercolino SF, Festa M, Gentilella A, Tosco A, Conzen SD, Parente L. 2006. Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer 42:3287-3293.
21. Reid IR. 1989. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 30:83-103.
22. Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL. 2005. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 333:42-50.
23. Runnebaum IB, Brüning A. 2005. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 11:6325-6332.
24. Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH. 2008. Combination of dexamethasone, high-dose cytarabine, and carboplatin Is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer 113:782-790.
25. Secchiero P, Zauli G. 2008. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42-48.
26. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. 2002.
27. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 100:2421-2429.
28. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G. 2007a. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403.
29. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G. 2007b. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61-69.
30. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS. 2005. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390-398.
31. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. 1998. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
32. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. 2002. Promotion of osteoclast survival and antagonism of bisphosphonateinduced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041-1048.
33. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G. 2000. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 95:3716-3724.
34. Zauli G, Secchiero P. 2006. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 17:245-257.
35. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. 2004. TNF-related apoptosis inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL+M-CSF. Blood 104:2044-2050.
36. Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117-125.
37. Zauli G, Melloni E, Capitani S, Secchiero P. 2009. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841-851.